Roche (RHHBY) News Today $39.26 +0.45 (+1.16%) (As of 05:44 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Roche announces phase III INAVO120 results were publishedNovember 1 at 3:18 PM | markets.businessinsider.comRoche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's diseaseOctober 31 at 2:15 AM | globenewswire.comNew England Journal of Medicine publishes landmark phase III results for Roche's Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancerOctober 31 at 2:00 AM | globenewswire.comDyno signs second Roche deal worth over $1BOctober 26, 2024 | bizjournals.comPharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory NewsOctober 25, 2024 | finance.yahoo.comRoche reports Q3 sales growth, driven by strong pharma performance and ActemraOctober 24, 2024 | investing.comUSA News Group: Health and Wellness Industry Embraces Surge in Demand for Weight Loss DrugsOctober 24, 2024 | finanznachrichten.deRoche reports 9M group sales CHF 44.98B vs. CHF 44.05B last yearOctober 24, 2024 | markets.businessinsider.comRoche sees 2024 core EPS growing in high single digit rangeOctober 24, 2024 | markets.businessinsider.comRoche reaffirms 2024 outlook after Q3 beatOctober 24, 2024 | msn.comRoche comes out against clearing takeover of drug manufacturer CatalentOctober 23, 2024 | reuters.comRoche Group Sales In Q3, 9M Rise; Confirms FY24 OutlookOctober 23, 2024 | markets.businessinsider.comRoche Q3 sales advance by forex-adj 9%, beating market viewOctober 23, 2024 | reuters.com[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine monthsOctober 23, 2024 | globenewswire.comCan Roche Challenge Lilly and Novo in the Weight Loss Market?One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.October 22, 2024 | marketbeat.comGenentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind StudyOctober 20, 2024 | businesswire.comGenentech announces topline one-year results from ELEVATUM studyOctober 20, 2024 | finance.yahoo.comRoche receives FDA approval for Ventana CLDN18 RxDx AssayOctober 20, 2024 | finance.yahoo.comPharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New DrugsOctober 19, 2024 | msn.comRoche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyOctober 19, 2024 | finance.yahoo.comELEVATUM Study:Roche' Vabysmo Enhances Vision In Underrepresented Diabetic Macular Edema PopulationsOctober 19, 2024 | markets.businessinsider.comGenentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind StudyOctober 18, 2024 | businesswire.comRoche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyOctober 18, 2024 | globenewswire.comRoche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYOctober 18, 2024 | prnewswire.comJazz Pharma gains on late-stage trial win for cancer drugOctober 17, 2024 | msn.comMajority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data DemonstrateOctober 14, 2024 | businesswire.comMajority of children with spinal muscular atrophy (SMA) treated with Roche's Evrysdi are able to sit, stand and walk independently, two-year data demonstrateOctober 14, 2024 | globenewswire.comRoche gets FDA approval for Itovebi combo therapy for breast cancerOctober 11, 2024 | seekingalpha.comRoche Gets FDA OK for ItovebiOctober 11, 2024 | marketwatch.comFDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationOctober 11, 2024 | finance.yahoo.comFDA approves Roche's Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationOctober 11, 2024 | globenewswire.comFDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA MutationOctober 10, 2024 | finance.yahoo.comThursday's Stock Trades: Palantir, Pfizer, and MoreOctober 10, 2024 | baystreet.caWeight-loss drugs: How much should investors worry about side effects?October 10, 2024 | msn.comRoche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYOctober 10, 2024 | globenewswire.comRoche CEO: breast cancer pill could be in 10 bln CHF market if trials succeedOctober 9, 2024 | reuters.comSurvey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general publicOctober 8, 2024 | prnewswire.comRoche Hldg is Now Oversold (RHHBY)October 6, 2024 | nasdaq.comBard Financial Services Inc. Increases Stake in Roche Holding AG (OTCMKTS:RHHBY)Bard Financial Services Inc. grew its position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 112.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,500 shares of the company's stock after purchasing an additiOctober 5, 2024 | marketbeat.comRoche Holding (OTC:RHHBY) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comRoche Sees Sales Momentum To Continue Into 2025; Aims To Deliver 20 New MedicinesSeptember 30, 2024 | markets.businessinsider.comRoche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales PotentialSeptember 30, 2024 | benzinga.comRoche targets more than $3 billion in annual obesity salesSeptember 30, 2024 | reuters.comRoche, Biogen kidney disease drug hits main goal in late-stage studySeptember 26, 2024 | msn.comPositive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritisSeptember 26, 2024 | finance.yahoo.comRoche's Gazyva/Gazyvaro Shows Superiority To Standard Therapy In Phase III Lupus Nephritis StudySeptember 26, 2024 | markets.businessinsider.comPositive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus NephritisSeptember 26, 2024 | businesswire.comPositive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritisSeptember 26, 2024 | globenewswire.comNext frontier in anti-obesity landscape: oral GLP-1s with potential OTC switchSeptember 25, 2024 | msn.comRoche Unveils Cobas Respiratory Flex Test For Simultaneous Detection Of 12 Respiratory VirusesSeptember 24, 2024 | markets.businessinsider.com Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025. Click here to see the surprising reason why RHHBY Media Mentions By Week RHHBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼-0.130.46▲Average Medical News Sentiment RHHBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼46▲RHHBY Articles Average Week Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aalberts News Absa Group News Airbus News Airports of Thailand Public News Amada News Asia Broadband News Avolta News Banca Monte dei Paschi di Siena News CCL Industries News China Gas News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 11/1/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | Sponsored4 Trades for $4?! (Next Pick Goes LIVE Tues!)Bryan wants show you his unique trading philosophy... It allows his members to take profits early again and...Monument Traders Alliance | SponsoredCapitalize on Generational Opportunities in the ‘Roaring 2020s’The industrial revolutions in our country's past have connected the world in ways never thought possible… C...Unstoppable Prosperity | SponsoredIf You’re Even Thinking of Investing in AI, Read This First.If you're starting to invest in AI or even just thinking about it, it can feel overwhelming and even a bit sca...Brownstone Research | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredIs your portfolio prepared for AI 2.0?AI has exploded ever since ChatGPT set the world on fire near the end of 2022. Numerous companies with conn...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.